Label Trial of C-1073 ( Mifepristone ) for Psychotic Major Depression *

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).

  2001cited by this paper
• Cortisol activity and cognitive changes in psychotic major depression.

  2001cited by this paper
• Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.

  2000cited by this paper
• Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness.

  2000cited by this paper
• Stress-Level Cortisol Treatment Impairs Inhibitory Control of Behavior in Monkeys

  2000cited by this paper
• Timing of onset of antidepressant response with fluoxetine treatment.

  2000cited by this paper
• Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain.

  2000cited by this paper
• Distribution of Corticosteroid Receptors in the Rhesus Brain: Relative Absence of Glucocorticoid Receptors in the Hippocampal Formation

  2000cited by this paper
• Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients.

  1999cited by this paper
• Antiglucocorticoid treatment of depression: double-blind ketoconazole.

  1999cited by this paper
• Selective serotonin reuptake inhibitors and delusional depression.

  1999cited by this paper
• Decreased memory performance in healthy humans induced by stress-level cortisol treatment.

  1999cited by this paper
• Long‐term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study

  1997cited by this paper
• DST studies in psychotic depression: a meta-analysis.

  1997influential reference
• Quantifying the speed of symptomatic improvement with electroconvulsive therapy: comparison of alternative statistical methods.

  1997cited by this paper
• [Pharmacological treatment of delusional depression].

  1996influential reference
• Mifepristone: treatment of Cushing's syndrome.

  1996cited by this paper
• Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.

  1996cited by this paper
• Fluvoxamine alone in the treatment of delusional depression.

  1996cited by this paper
• Endometrial effects of long-term low-dose administration of RU486.

  1995cited by this paper
• Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

  1995cited by this paper
• Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect.

  1995cited by this paper
• Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.

  1994cited by this paper
• Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.

  1993cited by this paper
• Ketoconazole administration in hypercortisolemic depression.

  1993cited by this paper
• Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.

  1993cited by this paper
• Inhibition of ovulation by low-dose mifepristone (RU 486).

  1992cited by this paper
• Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?

  1992cited by this paper
• The endocrine effects of long-term treatment with mifepristone (RU 486).

  1991cited by this paper
• Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486).

  1991cited by this paper
• Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis.

  1991cited by this paper
• Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression.

  1990cited by this paper
• Effect of the anesthetic agent propofol on hormonal responses to ECT.

  1990cited by this paper
• Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects.

  1990cited by this paper
• Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.

  1988cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988influential reference
• Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants.

  1987influential reference
• Urinary free cortisol in psychotic depression.

  1987cited by this paper
• Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase.

  1987cited by this paper
• Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase.

  1987cited by this paper
• Delusional depression: tricyclic response.

  1986influential reference
• Delusional and nondelusional unipolar depression: further evidence for distinct subtypes.

  1986cited by this paper
• Afternoon increase in plasma cortisol in depressed patients receiving an antiglucocorticosteroid in the morning.

  1986cited by this paper
• Delusional depression: phenomenology and response to treatment

  1986cited by this paper
• Delusional depression. A one year follow-up.

  1985influential reference
• Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.

  1985cited by this paper
• Delusional depression: a review of the literature and current perspectives

  1985influential reference
• A corticosteroid/dopamine hypothesis for psychotic depression and related states.

  1985cited by this paper
• Electroconvulsive Therapy-Induced Cortisol Release: Changes with Depressive State.

  1985cited by this paper
• Subtypes of depression. Family study perspective.

  1984cited by this paper
• The Clinical and Neuroendocrine Features of Psychotic Depression

  1984cited by this paper
• RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.

  1984cited by this paper
• Delusional depression. Phenomenology, Neuroendocrine function, and tricyclic antidepressant response.

  1984cited by this paper
• The dexamethasone suppression test in psychotic disorders.

  1983cited by this paper
• 80. Potent antiglucocorticoid activity of RU38486 on acth secretion in vitro and in vivo in the rat

  1982cited by this paper
• The mean 1300-1600 h plasma cortisol concentration as a diagnostic test for hypercortisolism.

  1982cited by this paper
• The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients

  1982cited by this paper
• Psychotic depression: a separate entity?

  1981cited by this paper
• Delusional depression. A distinct clinical entity?

  1981cited by this paper
• Depression treated with imipramine and ECT: the DeCarolis study reconsidered.

  1979cited by this paper
• The Treatment of Psychotic Major Depressive Disorder with Drugs and Electroconvulsive Therapy

  1979cited by this paper
• Delusional Depressions: Natural History and Response to Treatment

  1977influential reference
• Depression, Delusions, and Drug Response.

  1975cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Exploring Therapeutic Potential: A Comprehensive Review of Novel Treatment Targets in Psychotic Depression

  2024cites this paper
• A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease.

  2024cites this paper
• Efficacy and Safety of Mifepristone in the Treatment of Male US Veterans With Posttraumatic Stress Disorder

  2023cites this paper
• Stress and the risk of Alzheimer dementia: Can deconstructed engrams be rebuilt?

  2023cites this paper
• Glucocorticoid feedback paradox: a homage to Mary Dallman

  2023cites this paper
• The HPA Axis as Target for Depression

  2023cites this paper
• Chronic administration of glucocorticoid receptor ligands increases anxiety-like behavior and selectively increase serotonin transporters in the ventral hippocampus.

  2022cites this paper
• Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics

  2021cites this paper
• Decoding the temporal nature of brain GR activity in the NFκB signal transition leading to depressive-like behavior

  2021cites this paper
• Efficacy of Treatments Targeting Hypothalamic-Pituitary-Adrenal Systems for Major Depressive Disorder: A Meta-Analysis

  2021cites this paper
• Reducing Allostatic Load in Depression and Anxiety Disorders: Physical Activity and Yoga Practice as Add-On Therapies

  2020cites this paper
• Causes and Consequences of Diagnostic Heterogeneity in Depression: Paths to Discovering Novel Biological Depression Subtypes.

  2020cites this paper
• Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics

  2020cites this paper
• Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence

  2020cites this paper
• HPA axis- Interaction with Behavioral Systems

  2020cites this paper
• Neurovascular glucocorticoid receptors and glucocorticoids: implications in health, neurological disorders and drug therapy.

  2020cites this paper
• New agents and perspectives in the pharmacological treatment of major depressive disorder.

  2020cites this paper
• Biomarking Trait Resilience With Salivary Cortisol in Chinese Undergraduates

  2020cites this paper
• The Brain Stress System in the Neurobiology of the “Dark Side” of Addiction and Its Relation to Neurodegeneration

  2020cites this paper
• Cortisol and Major Depressive Disorder—Translating Findings From Humans to Animal Models and Back

  2020cites this paper
• An Overview of Depression and Two Antidepressants --Selegiline and Fluoxetine

  2020cites this paper
• Intracellular Signaling Cascades in Bipolar Disorder.

  2020cites this paper
• Long-term effects of the glucocorticoid receptor modulator cort 113176 in murine motoneuron degeneration.

  2019cites this paper
• Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis.

  2019cites this paper
• Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets

  2019cites this paper
• For submission to Psychoneuroendocrinology Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: a meta-analysis

  2019cites this paper
• Daily hassles, loneliness, and diurnal salivary cortisol in emerging adults.

  2019cites this paper
• Affect and Vulnerability for Psychostimulant Relapse

  2019cites this paper
• Corticosteroid Action in the Brain: The Potential of Selective Receptor Modulation

  2019cites this paper
• Resetting the Stress System with a Mifepristone Challenge

  2018cites this paper
• Central Role of Glucocorticoid Receptors in Alzheimer’s Disease and Depression

  2018cites this paper
• Mifepristone as a Psychopharmacologic Agent: Consideration of Efficacy, Plasma Levels, and Mechanism of Action.

  2018cites this paper
• Novel Therapeutics in Bipolar Disorder

  2018cites this paper
• Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders.

  2018cites this paper
• International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets

  2018cites this paper
• Glucocorticoid receptor activation induces decrease of hippocampal astrocyte number in rats

  2018cites this paper
• Transcriptional regulation of corticotropin-releasing hormone gene in stress response

  2018cites this paper
• 12 An Update on Psychotic Depression

  2018cites this paper
• Adolescent stress leads to glutamatergic disturbance through dopaminergic abnormalities in the prefrontal cortex of genetically vulnerable mice

  2017cites this paper
• Footshock‐induced plasticity of GABAB signalling in the lateral habenula requires dopamine and glucocorticoid receptors

  2017cites this paper
• Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression

  2017cites this paper
• The Hippocampus as a Neural Link between Negative Affect and Vulnerability for Psychostimulant Relapse

  2017cites this paper
• The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa.

  2017cites this paper
• The glucocorticoid receptor in the limbic system of the human brain

  2016cites this paper
• Mineralocorticoid and glucocorticoid receptor balance in memory systems: Development and mechanism

  2016cites this paper
• Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol

  2016cites this paper
• Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression

  2016cites this paper
• Chronic distress and the vulnerable host: a new target for HIV treatment and prevention?

  2016cites this paper
• Antiglucocorticoid and related treatments for psychosis.

  2016cites this paper
• HPA Axis Interactions with Behavioral Systems.

  2016cites this paper
• Anhedonia in Major Depressive Disorder: Exploration of a Predictive Clinical Phenotype

  2015cites this paper
• Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamic–pituitary–adrenal (HPA) axis in the pathogenesis of psychotic major depression

  2015cites this paper
• Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

  2015cites this paper
• Antiglucocorticoid treatments for mood disorders.

  2015cites this paper
• Development of New Psychopharmacological Agents for Depression and Anxiety.

  2015cites this paper
• Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

  2015cites this paper
• Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

  2015cites this paper
• Antiglucocorticoid treatments for mood disorders (Withdrawn Paper. 2015, Art. no. CD005168)

  2015cites this paper
• Mifepristone modulates serotonin transporter function

  2014influential citation
• Dissecting the functional and morphological contributions of the glucocorticoid receptor gene in neural progenitor cells of the hippocampus

  2014cites this paper
• Fresh approaches to antidepressant drug discovery

  2014cites this paper
• The Relationship of Serum Cortisol Levels with Depression, Cognitive Function and Sleep Disorders in Chronic Kidney Disease and Hemodialysis Patients

  2014cites this paper
• Fear Learning as a Component of a Depressive Phenotype in Rodents

  2014cites this paper
• Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects.

  2014cites this paper
• Cortisol administration induces global down-regulation of the brain's reward circuitry.

  2014cites this paper
• The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.

  2014cites this paper
• The depressogenic-like effect of acute and chronic treatment with dexamethasone and its influence on the activity of antidepressant drugs in the forced swim test in adult mice.

  2014cites this paper
• Role of corticosteroids in the antidepressant response

  2014cites this paper
• Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits.

  2013cites this paper
• Cytokines as biomarkers in depressive disorder: Current standing and prospects

  2013cites this paper
• Clinical Handbook for the Management of Mood Disorders

  2013cites this paper
• Mineralocorticoid receptor blockade prevents stress-induced modulation of multiple memory systems in the human brain.

  2013cites this paper
• Stress and excitatory synapses: from health to disease.

  2013influential citation
• The glucocorticoid antagonist RU-486 suppresses HIV infectivity and replication.

  2013cites this paper
• Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients.

  2013cites this paper
• The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.

  2013cites this paper
• The Effects of Ketamine on Cognitive Bias in a Stress Vulnerable Chick Strain

  2013cites this paper
• The role of inflammatory cytokines on the aetiopathogenesis of depression

  2013cites this paper
• A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression.

  2012cites this paper
• Receptor Polymorphisms in Major Depression: Focus on glucocorticoid sensitivity and neurocognitive functioning

  2012cites this paper
• Chronic non-invasive corticosterone administration abolishes the diurnal pattern of tph2 expression.

  2012cites this paper
• Gap Junction Dysfunction in the Prefrontal Cortex Induces Depressive-Like Behaviors in Rats

  2012cites this paper
• A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness

  2012cites this paper
• conceptUal stUdy

  2012cites this paper
• Noradrenergic activity regulated dexamethasone-induced increase of 5-HT₃ receptor-mediated glutamate release in the rat's prelimbic cortex.

  2012cites this paper
• Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia

  2012cites this paper
• The effects of early corticosterone treatment on the development of the avian song control system

  2012cites this paper
• An Update on Psychotic Depression

  2012cites this paper
• Examining reelin expression and neural plasticity in animal models of depression

  2012cites this paper
• Drugs in the medical treatment of Cushing's syndrome – an update on mifepristone and pasireotide

  2012cites this paper
• Psychotic Depression—Beyond the Antidepressant/Antipsychotic Combination

  2012cites this paper
• Metyrapone in treatment-resistant depression

  2012cites this paper
• Central Dopaminergic System and Its Implications in Stress-Mediated Neurological Disorders and Gastric Ulcers: Short Review

  2012cites this paper
• A Pilot Study of Mifepristone in Combat-Related PTSD

  2012cites this paper
• Association between functional polymorphism of the AVPR1b gene and polymorphism rs1293651 of the CRHR1 gene and bipolar disorder with psychotic features.

  2012cites this paper
• Cognitive bias in the chick anxiety-depression model.

  2011cites this paper
• Glucocorticoids as Predictors of Treatment Response in Depression

  2011cites this paper
• Etude de l'implication fonctionnelle du système orexinergique dans les mécanismes physiopathogéniques de la dépression majeure

  2011cites this paper
• Stress, emotional learning and AMPA receptors: from behavior to molecule

  2011cites this paper
• Corticotropin-Releasing Hormone, Glutamate, and γ-Aminobutyric Acid in Depression

  2011cites this paper